FY2024 EPS Estimates for Cencora, Inc. (NYSE:COR) Reduced by Leerink Partnrs

Cencora, Inc. (NYSE:COR) – Leerink Partnrs reduced their FY2024 earnings per share (EPS) estimates for Cencora in a research note issued on Wednesday, May 1st. Leerink Partnrs analyst M. Cherny now forecasts that the company will post earnings of $13.46 per share for the year, down from their prior estimate of $13.51. Leerink Partnrs currently has a “Outperform” rating on the stock. The consensus estimate for Cencora’s current full-year earnings is $13.44 per share. Leerink Partnrs also issued estimates for Cencora’s Q1 2025 earnings at $3.48 EPS, Q3 2025 earnings at $3.72 EPS, Q4 2025 earnings at $3.70 EPS and FY2026 earnings at $16.54 EPS.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, May 1st. The company reported $3.80 earnings per share for the quarter, beating analysts’ consensus estimates of $3.65 by $0.15. Cencora had a net margin of 0.67% and a return on equity of 268.67%. The business had revenue of $68.41 billion for the quarter, compared to analyst estimates of $70.60 billion. During the same period last year, the business earned $3.50 EPS. The company’s revenue was up 7.8% on a year-over-year basis.

Other equities analysts also recently issued reports about the company. SVB Leerink began coverage on Cencora in a report on Monday, February 26th. They issued an “outperform” rating and a $261.00 price target for the company. Citigroup lifted their target price on Cencora from $265.00 to $280.00 and gave the stock a “buy” rating in a research report on Tuesday, April 30th. Mizuho lifted their price target on Cencora from $192.00 to $224.00 and gave the stock a “neutral” rating in a research report on Monday, February 5th. Robert W. Baird raised their target price on shares of Cencora from $275.00 to $277.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, StockNews.com cut shares of Cencora from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $233.90.

Cencora Trading Down 0.4 %

NYSE:COR opened at $223.95 on Monday. The company has a debt-to-equity ratio of 3.41, a quick ratio of 0.52 and a current ratio of 0.89. Cencora has a 1 year low of $163.37 and a 1 year high of $246.75. The stock has a market cap of $44.67 billion, a P/E ratio of 24.50, a P/E/G ratio of 1.68 and a beta of 0.47. The stock has a 50-day simple moving average of $238.31 and a 200-day simple moving average of $219.36.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in COR. Rise Advisors LLC purchased a new position in Cencora during the 1st quarter valued at about $25,000. Legacy Bridge LLC acquired a new position in shares of Cencora during the 1st quarter worth approximately $27,000. WASHINGTON TRUST Co acquired a new position in shares of Cencora during the 1st quarter worth approximately $32,000. Hanson & Doremus Investment Management acquired a new stake in Cencora during the 1st quarter valued at $33,000. Finally, OFI Invest Asset Management purchased a new position in Cencora during the first quarter worth $33,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Insider Activity at Cencora

In other Cencora news, major shareholder Walgreens Boots Alliance, Inc. sold 4,212,395 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $235.41, for a total value of $991,639,906.95. Following the completion of the sale, the insider now owns 26,277,561 shares of the company’s stock, valued at $6,186,000,635.01. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other Cencora news, major shareholder Walgreens Boots Alliance, Inc. sold 4,212,395 shares of the company’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $235.41, for a total transaction of $991,639,906.95. Following the transaction, the insider now directly owns 26,277,561 shares in the company, valued at $6,186,000,635.01. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Robert P. Mauch sold 57,564 shares of Cencora stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $235.09, for a total transaction of $13,532,720.76. Following the sale, the chief operating officer now owns 24,412 shares of the company’s stock, valued at $5,739,017.08. The disclosure for this sale can be found here. Insiders have sold a total of 4,288,790 shares of company stock worth $1,009,641,379 over the last three months. 15.80% of the stock is currently owned by corporate insiders.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 24th. Stockholders of record on Friday, May 10th will be issued a $0.51 dividend. The ex-dividend date is Thursday, May 9th. This represents a $2.04 annualized dividend and a dividend yield of 0.91%. Cencora’s dividend payout ratio is currently 22.32%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.